Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/121721
Title: Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia : a randomized clinical trial
Authors: Zhu, Xiaohang
Zhao, Lingying
Riva, Nicoletta
Yu, Ziqiang
Jiang, Miao
Zhou, Feng
Gatt, Alexander
Giannoudis, Peter V.
Guo, Jiong Jiong
Keywords: Blood platelet disorders
Thrombocytopenia
Osteoarthritis
Clinical trials
Issue Date: 2024
Publisher: Cell Press
Citation: Zhu, X., Zhao, L., Riva, N., Yu, Z., Jiong, M., Zhou, F., Gatt, A., Giannoudis, P. V. & Guo, J. J. (2024). Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia : a randomized clinical trial. iScience, 27(5), 109664.
Abstract: The treatment of painful KOA in adult patients with ITP has not been well studied yet. We conducted a prospective, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of intra-articular allogeneic PRP injections on symptoms and joint structure in patients with KOA and ITP. 80 participants were randomly allocated in a 1:1 ratio to allogeneic PRP group or saline group. The primary outcome was the WOMAC total score at 12 months post-injection. The number of patients in each group who achieved MCID of primary outcome showed a statistically significant difference only at 3-month (27/39 vs. 5/39, p = 0.001) and 6-month (15/39 vs. 3/38, p = 0.032). The difference in WOMAC total score exceeded the MCID only at 3 month (mean difference of -15.1 [95% CI -20.7 to -9.5], p < 0.001). Results suggest that allogeneic PRP was superior to placebo only with respect to symptoms at 3-month of follow-up.
URI: https://www.um.edu.mt/library/oar/handle/123456789/121721
Appears in Collections:Scholarly Works - FacM&SPat

Files in This Item:
File Description SizeFormat 
2- Zhu 2024.pdf3.74 MBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.